Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining attention in the global health industry for its potential anti-aging benefits, DNA repair, and metabolic regulation, with significant regulatory advancements expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial applications, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2][19]. NMN Definition and Function - NMN is a direct precursor to NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - As NAD+ levels decline with age, NMN supplementation can quickly elevate NAD+ levels, playing a vital role in anti-aging, cardiovascular health, and metabolic improvement [4][6]. Regulatory Environment - The global regulatory landscape for NMN is shifting from strict restrictions to cautious openness, with significant milestones achieved in various countries [17][18]. - In China, NMN has been approved as a new cosmetic ingredient and is on the path to being recognized as a health food, with the National Market Supervision Administration listing it for health food approval in April 2025 [17][18]. Market Demand - The aging population in China is expected to grow significantly, with the elderly population projected to increase from 320 million to 390 million by 2030, driving demand for anti-aging products [19]. - Younger generations are also increasingly aware of anti-aging needs, creating a dual demand for NMN products [19]. Technological Innovations - Advances in synthesis methods, particularly the full enzyme method, are driving down costs and improving product quality in the NMN industry [21][22]. - Innovations in delivery technologies are enhancing the bioavailability of NMN, ensuring better absorption and user experience [22]. Application Areas - NMN is primarily used in health supplements and cosmetics, with health supplements accounting for nearly 90% of the market share [24][28]. - Future applications are expected to expand into pet nutrition, medical health, and agricultural technology, opening new growth avenues [24][28]. Market Size and Growth - The NMN market in China is expected to exceed 3 billion yuan by 2025, driven by increasing regulatory support and expanding applications [28][32]. - The market is currently dominated by health supplements and cosmetics, with significant growth potential in other sectors as regulations ease [28][32]. Sales Channels - NMN products are primarily sold through cross-border e-commerce and private channels, with cross-border e-commerce accounting for 60%-70% of market share [35][34]. Certification and Standards - The "blue hat" certification for health foods in China represents the highest standard for NMN products, indicating safety and compliance [37]. Challenges and Opportunities - The NMN industry faces challenges such as exaggerated claims, lack of consumer awareness, and technological iterations, necessitating a focus on compliance and innovation [61][63]. - Companies are encouraged to innovate their business models and extend their value chains to enhance competitiveness [66].

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining global attention in the health industry due to its potential in anti-aging, DNA repair, and metabolic regulation, with significant advancements in regulatory approval and market potential expected by 2025 [1][2]. Group 1: NMN Definition and Function - NMN is a direct precursor to NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - Supplementing NMN can rapidly increase NAD+ levels in the body, playing a vital role in anti-aging, cardiovascular health, and cognitive function [4][6]. Group 2: Global Regulatory Landscape - By 2025, NMN's global compliance process is expected to accelerate, with major markets like the US, Japan, Canada, and Australia confirming its legal status through various regulatory pathways [1][2]. - In China, NMN has not yet received approval as a drug or health food, but it has been recognized as a new cosmetic ingredient, laying the groundwork for future regulatory developments [1][17]. Group 3: Market Demand Drivers - The aging population in China is projected to grow significantly, with the elderly population expected to increase from 320 million to 390 million between 2025 and 2030, driving the "silver economy" and demand for anti-aging products [19]. - Younger generations, particularly those born in the 1990s, are increasingly aware of anti-aging needs, creating a dual demand for NMN products [19]. Group 4: Technological Innovations - Continuous innovations in synthesis, quality testing, and delivery methods are driving the NMN industry forward, with full enzyme methods significantly enhancing production efficiency and reducing costs [21][22]. - The establishment of testing standards is raising industry entry barriers, promoting market development [22]. Group 5: Current Market Status - The NMN market in China has been expanding rapidly since its large-scale entry in 2020, with expectations to exceed 3 billion yuan by 2025 [28]. - NMN is primarily used in health supplements (approximately 90% of applications) and cosmetics (10-20%), with potential future applications in pet nutrition, medical health, and agricultural technology [24][28]. Group 6: Sales Channels - NMN products are mainly sold through cross-border e-commerce and private channels, with cross-border e-commerce accounting for 60-70% of the market share [35]. Group 7: Industry Challenges - The NMN industry faces challenges such as exaggerated claims, lack of consumer awareness, and the need for technological iteration, necessitating a focus on compliance and innovation to unlock market potential [61][63].

Group 1 - The core point of the article is that Jindawei (002626.SZ) has completed the development of its You series functional beverages, which are not yet officially on sale [1] Group 2 - The company has communicated this information through its investor interaction platform [1]

格隆汇2月13日丨金达威(002626.SZ)在投资者互动平台表示，公司尚未规划在国内销售辅酶Q10饮品。 ...

| 证券代码：002626 | 证券简称：金达威 | 公告编号：2026-018 | | --- | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | | 1、证券代码：002626，证券简称：金达威 2、债券代码：127111，债券简称：金威转债 3、转股价格：19.59 元/股 4、转股期起止日期：2026 年 2 月 26 日至 2031 年 8 月 19 日 司债券募集说明书》（以下简称"《募集说明书》"）的约定，公司本次发行的 可转换公司债券的转股期自 2026 年 2 月 26 日至 2031 年 8 月 19 日。 厦门金达威集团股份有限公司 关于金威转债开始转股的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 5、转股股份来源：新增股份 一、可转债上市发行概况 根据中国证券监督管理委员会出具的《关于同意厦门金达威集团股份有限公 司向不特定对象发行可转换公司债券注册的批复》（证监许可〔2024〕1567 号）， 厦门金达威集团股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日向 ...

Core Insights - The Chinese nutrition and health industry is experiencing a surge in IPO activities, indicating a shift from local operations to global expansion and a focus on scientific validation [4][5]. IPO Developments - In 2025, several companies in the nutrition and health sector are set to go public, covering the entire supply chain from raw materials to manufacturing and branding [4]. - Dongpeng Beverage plans to list on the Hong Kong Stock Exchange in early 2026, aiming to raise over HKD 10.1 billion, marking the largest IPO in the non-alcoholic beverage sector in Hong Kong history [4]. - Xianle Health is advancing its H-share listing while optimizing its global CDMO platform by divesting non-core assets [4]. - Ruoyuchen has submitted its application to the Hong Kong Stock Exchange, focusing on its proprietary brand FineNutri to transition from a service provider to a brand owner [4]. - Other companies like Jiyuan Group and Hengmei Health are also pursuing listings to enhance their production capacities and market presence [4][5]. Regulatory Updates - The National Market Supervision Administration has released several guidelines and regulations affecting the health and nutrition sector, including the review of special medical formula food production licenses and the management of live-streaming e-commerce [6][7]. - New regulations have been introduced to ensure compliance in the marketing of health products, including a ban on certain food sales in live-streaming environments [6]. Market Trends - There is a notable increase in demand for health supplements, with sales of ginseng and other tonic products rising by 55% year-on-year during the New Year holiday [17]. - The import of medical and health products has also seen significant growth, with a 70.4% increase in imports in Hubei province in 2025 [17]. Industry Insights - The current wave of capital influx is not merely for financing but signals a critical transition in the industry towards scientific validation and global operations [4]. - Companies with genuine research capabilities, compliant product systems, and international perspectives are expected to gain a competitive edge in high-quality development [4].

| 证券代码：002626 | 证券简称：金达威 公告编号：2026-017 | | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | 张（含息税），回售申报期为 2026 年 1 月 29 日至 2026 年 2 月 4 日。 厦门金达威集团股份有限公司 关于"金威转债"回售结果的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 一、本次可转换公司债券回售的公告情况 根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管 指引第 15 号——可转换公司债券》等相关规定，以及《厦门金达威集团股份有 限公司向不特定对象发行可转换公司债券募集说明书》的约定，厦门金达威集团 股份有限公司（以下简称"公司"）分别于 2026 年 1 月 28 日、2026 年 1 月 29 日、2026 年 1 月 31 日、2026 年 2 月 3 日在公司指定信息披露媒体《证券时报》 《证券日报》和巨潮资讯网上分别披露了《关于金威转债回售的公告》《关于金 威转债回售的第一次提示性公告》《关于金威转债回售的第二次提示性公告》 ...

Core Viewpoint - The company and its subsidiaries have been granted a patent for an invention related to carbonyl reductase mutants and their applications, which is expected to enhance technological innovation and core competitiveness, although it will not have a significant impact on production and operations [1] Group 1 - The patent granted is for the invention titled "Carbonyl Reductase Mutant and Its Preparation Method, Application, and Preparation Method of ®-6-Hydroxy-8-Chlorooctanoic Acid Ethyl Ester" [1] - The patent number is ZL202211709938.1, with a validity period of 20 years [1] - The official announcement date of the patent is January 30, 2026 [1] Group 2 - The patent is expected to contribute to technological innovation within the company [1] - The patent will enhance the company's core competitiveness in the industry [1] - The company does not anticipate any major impact on its production and operations from this patent [1]

广发证券股份有限公司 关于厦门金达威集团股份有限公司 预计2026年度日常关联交易的核查意见 广发证券股份有限公司（以下简称"保荐人"）作为厦门金达威集团股份有 限公司（以下简称"金达威"或"公司"）持续督导的保荐人，根据《证券发行 上市保荐业务管理办法》《深圳证券交易所股票上市规则》《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》《深圳证券交易所上市 公司自律监管指引第 7 号——交易与关联交易》等相关法律、法规和规范性文件 的规定，对公司预计 2026 年度日常关联交易事项进行了核查，具体情况如下： 一、预计2026年度日常关联交易基本情况 因业务发展的需要，公司预计 2026 年度与关联方中牧实业股份有限公司（以 下简称"中牧股份"）及所属子公司存在部分必要的、合理的关联交易，主要涉 及销售/采购商品，预计销售金额不超过 3,100.00 万元、采购金额不超过 100.00 万元。关联董事顾卫华先生、徐肖特先生回避表决。 上述议案已经公司独立董事专门会议 2026 年第一次专门会议审议通过，独 立董事全票同意将该议案提交董事会审议。本事项在公司董事会审批权限范围内， 无需提交股 ...

| 证券代码：002626 | 证券简称：金达威 | 公告编号：2026-016 | | --- | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | | 厦门金达威集团股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）及子公司金达威生物技 术（江苏）有限公司、厦门金达威维生素有限公司，近日收到国家知识产权局颁 发的 1 件发明专利证书，具体情况如下： 发明名称：羰基还原酶突变体及其制备方法、应用和(R)-6-羟基-8-氯辛酸乙 酯的制备方法 专利号：ZL 2022 1 1709938.1 上述专利的取得不会对公司生产经营产生重大影响，但有利于公司的技术创 新，充分发挥自主知识产权优势，进一步完善知识产权保护体系，增强公司的核 心竞争力。 专利申请日：2022 年 12 月 29 日 专利权人：金达威生物技术（江苏）有限公司 厦门金达威维生素有限公司 厦门金达威集团股份有限公司 特此公告。 专利权期限：二十年 厦门金达威集团股份有限公司 证书号： ...